Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2000

View Archived Issues

Ligand presents data on novel rexinoid with potential in diabetes and obesity therapy

Extended-release metformin shows good phase I results

Vion accomplishes several achievements during 1999

Palatin Technologies and Molecular Biosystems' merger on track

Millennium commences phase II clinical trial of LDP-02 for treatment of Crohn's disease

Phase III trial evaluating beraprost as treatment for moderate pulmonary hypertension

PDL initiates phase I trial of SMART anti-interferon gamma antibody

Dosing begins in phase II trial of Alprox-TD for erectile dysfunction

ImmunoGen and SUNY to develop novel taxane compounds

Ilex Oncology achieves important milestones in 1999

Patent issued to the former HMR for new series of bone resorption inhibitors

Ariad's GVHD therapy receives orphan drug status

Potent and selective human 5-HT2A receptor antagonists designed at MS&D

New respiratory therapeutics from Zambon act as phosphodiesterase inhibitors

Licensing opportunity from OMRF: therapeutic uses of aspartame

Valdecoxib: profile of an up-and-coming COX-2 inhibitor

Jefferson researchers develop effective oral vaccine for neurological disorders

Pfizer presents new urokinase inhibitors for wound healing, etc.

Novel approach to cardiovascular disorders described by SB

Discovery to develop aerosolized formulations of Surfaxin

Hypnotic alpha-amino acid phenyl ester derivatives in development at Akzo Nobel

High-affinity, selective human A3 receptor radioligand: synthesis and preliminary testing

ValiGene and Kimeragen to merge

Potent human Y5 receptor antagonists bearing a novel heterocyclic core prepared at RWJPRI

Progenics and Genzyme Transgenics continue PRO-542 development

March Oncologic Drugs Advisory Committee meeting to review three NDAs

Zyvox to be reviewed by FDA committee in late March

Novel triazole antifungal agents reported in Chinese literature